Mortality due to non small cell lung cancers is the first cause of cancer death in men around the world. Lung adenocarcinoma regularly induces bone metastases responsible for high morbidity and impaired life quality. Overall survival of these patients is poor. Thus the investigators aimed to identify if some bone and metabolic parameters were associated with overall survival. Patients and Methods POUMOS is a prospective cohort of patients suffering from adenocarcinoma lung cancers with a first bone metastasis (stage IV). All patients have a bone biopsy with molecular status characterization of the tumor for EGFR, KRAS, BRAF and ALK. Bone metastasis localizations are obtained by bone scintigraphy or FDG-PET/CT. Whole body composition is obtained by DEXA scan (Hologic®). The investigators assessed also fasting blood levels of bone and metabolic biomarkers. Survival analyses will be performed using a proportional hazard regression model.
Study Type
OBSERVATIONAL
Enrollment
200
The vast majority of bone biopsy are performed under CT-scan. In some rare cases, the histology will be performed during surgery (either biopsy of the bone metastasis or surgical piece when treating a fracture).
Hospices Civils de Lyon - Hôpital Edouard Herriot - Centre des Métastases Osseuses (CEMOS)
Lyon, France
serum DKK1
Biomarkers are assessed at baseline.
Time frame: day 0
serum HbA1C
Biomarkers are assessed at baseline
Time frame: day 0
urinary CTX
Biomarkers are assessed at baseline
Time frame: day 0
hip bone mass (g/cm²)
Whole body densitometry is performed at baseline
Time frame: day 0
mutational profile of the bone metastases
Molecular characterization of the bone metastases by PCR (EGFR, KRAS, BRAF) and FISH (ALK)
Time frame: day 0
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.